Previous 10 | Next 10 |
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, wi...
InflaRx (NASDAQ:IFRX): Q3 GAAP EPS of -$0.27 beats by $0.09. Cash and cash equivalents of €70.0 million as of September 30, 2021 Press Release Shares -4.7% PM For further details see: InflaRx EPS beats by $0.09
Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for Phase III program with vilobelimab in HS In Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum, 6 out of 7 patient...
JENA, GERMANY, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, wi...
Gainers: HCW Biologics (NASDAQ:HCWB) +132%. InflaRx (NASDAQ:IFRX) +45%. Digital Brands Group (NASDAQ:DBGI) +43%. Lucid Group (NASDAQ:LCID) +38%. Wolfspeed (NASDAQ:WOLF) +32%. LendingClub Corporation (NYSE:LC) +32%. Overstock (NASDAQ:OSTK) +25%. Impinj (NASDAQ:PI) +24%. Triterras (NASDAQ:TRIT)...
Gainers: HCW Biologics HCWB +115%, InflaRx IFRX +40%, Inspira Technologies Oxy (NASDAQ:IINN) +37%, Community Health Systems (NYSE:CYH) +16%, Invacare (NYSE:IVC) +11%. Losers: Rafael RFL -80%, DBV Technologies (NASDAQ:DBVT) -13%, Alny...
HCW Biologics (NASDAQ:HCWB) +102% after FDA greenlight for HCW9218 pancreatic cancer study InflaRx (NASDAQ:IFRX) +61% as Raymond James upgrades expecting price to quadruple LendingClub (NYSE:LC) +32% on Q3 earnings. DatChat (NASDAQ:DATS) +15% launches social...
InflaRx (NASDAQ:IFRX) has added ~65.4% in the pre-market after Raymond James raised its rating to Strong Buy from Outperform. The upgrade comes a day after the company reported positive Phase 2a data for its experimental C5a antibody, vilobelimab (IFX-1) in Pyoderma Gangraenosu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re kicking off Thursday with a dive into the biggest pre-market stock movers traders will want to watch today! Source: Shutterstock News moving stocks this morning includes earnings...
Guardion Health Sciences (NASDAQ:GHSI) +53%. RISE Education Cayman (NASDAQ:REDU) +20% on receipt of prelim non-bidding proposal to acquire all company assets Kaival Brands Innovations (NASDAQ:KAVL) +25% FDA enters administrative stay of Bidi Vapor's marketing denial order for i...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...